Author

I. Pratumchai

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:cell type annotation· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Assay:ChIP-seq· 1 Assay:clinical cohort / trial· 1

Frequent Co-Authors

J. Teijaro· 2 shared J. Zak· 2 shared A. Domissy· 1 shared B. Dinner· 1 shared B. S. Marro· 1 shared E. W. Weber· 1 shared J. A. Varner· 1 shared J. R. Teijaro· 1 shared

Activity by Year

2022-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 18 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

J. Teijaro

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Autoimmunity associated allele of tyrosine phosphatase gene PTPN22 enhances anti-viral immunity

R. C. Orozco, K. Marquardt, I. Pratumchai, K. Mowen, A. Domissy, J. R. Teijaro, L. A. Sherman

The study shows that the PTPN22 1858C>T allele, linked to autoimmunity, enhances anti-viral immunity by improving CD4 T cell responses and CD8-cDC function during LCMV infection.

bioRxiv · Jun 28, 2023 · PreprintImmunology

Transient EZH2 suppression by Tazemetostat during in vitro expansion maintains T cell stemness and improves adoptive T cell therapy

Y. Hou, J. Zak, Y. Shi, I. Pratumchai, B. Dinner, W. Wang, K. Qin, E. W. Weber, J. Teijaro, P. Wu

The paper shows that transient EZH2 inhibition with Tazemetostat during T cell expansion maintains stemness and improves adoptive T cell therapy outcomes in a murine model.

bioRxiv · Feb 7, 2023 · PreprintImmunology

Myeloid reprogramming by JAK inhibition enhances checkpoint blockade therapy

J. Zak, I. Pratumchai, B. S. Marro, K. L. Marquardt, R. Beheshti Zavareh, L. L. Lairson, M. B. A. Oldstone, J. A. Varner, V. Bachanova, J. Teijaro

Ruxolitinib reshapes myeloid immunity to synergize with checkpoint inhibitors, enhancing anti-tumor T cell activity and improving immunotherapy outcomes.

bioRxiv · Jun 24, 2022Immunology